Letters to the Editor

Primary outcomes by 1q21+ status for isatuximab-treated patients with relapsed/refractory multiple myeloma: Subgroup analyses from ICARIA-MM and IKEMA

UCSF Medical Center, San Francisco, CA
Dana-Farber Cancer Institute, Boston, MA
Department of Haematology, Lille University Hospital, Lille
Department of Hematology, University Hospital of Nantes, Nantes
Centre Hospitalo-Universitaire (CHU) de Toulouse, Centre de Recherches en Cancérologie de Toulouse (CRCT), Institut Universitaire du Cancer de Toulouse-Oncopole (IUCT-O), Université de Toulouse, UPS, Toulouse
First Department of Medicine, Department of Hematology, First Faculty of Medicine, Charles University and General Hospital, Prague, Czech Republic
Sanofi, Research and Development, Cambridge, MA
IT-M Statistics for Sanofi, Neuilly sur-Seine
IVIdata for Sanofi, Levallois-Perret
Sanofi, Research and Development, Vitry-Sur-Seine
Sanofi, Research and Development, Cambridge, MA
Department of Hematology, Japanese Red Cross Medical Center, Tokyo
Haematologica Early view Jun 23, 2022 https://doi.org/10.3324/haematol.2022.280660